📊 Note: Daily ratings and analytics are updated after market close and will be available by 7:00 PM IST.

Details

NameSymbolSector
RPG LIFE SCIENCES LIMITEDRPGLIFEPharmaceuticals
Open
2300
High
2330.9
Low
2269.9
Close
2274.2
Volume
3758
Exchange
nse
Time
21-May-2026

Outlook

Score:

4.25

Rating:

FAIR

Candlestick Pattern

CandlepatternofRpgLifeSciencesis
None
EstimatedStoplossofRpgLifeSciencesis
2330.9
RpgLifeScienceshasa
Bearishℹ
pattern.
Formationof
None
candlepatternindicatesthetrenddirectionofRpgLifeSciencesis
Unpredictableℹ
.

Trend

RpgLifeSciencesisin
Sideways trendℹ
.
PriceofRpgLifeSciencesis
Upℹ
by

7.94

%.
Target
Buy@

1611.86

Sell@

2421.46

Current@

2274.2

Volume

ThetradevolumesofRpgLifeScienceshavebecome
Deficientℹ
ThoughthevolumetrendforRpgLifeSciencesappears
Bullishℹ
theparticipantsseemtobe
Weak Buyersℹ
ThetradevolumeofRpgLifeSciencesis

Down

by

91.43

%

Valuation

ThecurrentmarketpriceofRpgLifeSciencesis
Undervaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth657crandtotalassetsworth657cr,thebalancesheetofRpgLifeSciencesis:
Balancedℹ
.
Cashflow
RpgLifeScienceshas
Maintainedℹ
cashflowbecausethereis

Surplus

of

₹ 8cr

.Itis
Upℹ
by

260

%.
53.1% i.e. ₹ 77cr earned in operatingℹ
28.28% i.e. ₹ 41cr spent in investingℹ
18.62% i.e. ₹ 27cr spent in financingℹ
0% in otherℹ
RpgLifeScienceshas
Poorℹ
cashflowbecausethereis

Shortage

of

₹ 5cr

.Itis
Upℹ
by

84.38

%.
48.7% i.e. ₹ 94cr earned in operatingℹ
40.93% i.e. ₹ 79cr spent in investingℹ
10.36% i.e. ₹ 20cr spent in financingℹ
0% in otherℹ
Income
TheincomeofRpgLifeSciencesis

₹ 186cr

and

Profit

is:

₹ 36cr

RpgLifeSciencesProfitisupby:

38.46

%andIncomeisUpby:

6.9

%
TheincomeofRpgLifeSciencesis

₹ 174cr

and

Profit

is:

₹ 26cr

RpgLifeSciencesProfitisdownby:

77.78

%andIncomeisUpby:

17.57

%
TheincomeofRpgLifeSciencesis

₹ 148cr

and

Profit

is:

₹ 117cr

RpgLifeSciencesProfitisupby:

244.12

%andIncomeisDownby:

15.91

%
By using this site you agree to the use of cookies to deliver a better site experience.